DR. FALK PHARMA GMBH vs. Ellodi Pharmaceuticals LP

Explore the PTAB proceeding IPR2024-01197 filed by DR. FALK PHARMA GMBH on 2024-07-22. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2024-01197

Filing Date

2024-07-22

Accorded Filing Date

2024-07-22

Institution Decision Date

2025-01-27

Last Modified Date

2026-01-13

Proceeding Type

IPR

Termination Date

2025-10-27

Trial Status

Terminated-Adverse Judgment

Parties & Counsel

Petitioner

DR. FALK PHARMA GMBH

Represented By

Luman, Nathanaelet al

Patent Owner / Respondent

Ellodi Pharmaceuticals LP

Represented By

Sukduang, Sanyaet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 12896005

Respondent Patent Number 8771729

External Links

Espacenet

Google Patents

Respondent Inventor Stephen Perrett et al

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

31 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name Cooley LLP / Eurand

Customer Number 91543

Address ATTN: Patent Group, 1299 Pennsylvania Avenue, Suite 700, Washington, DC, 20004, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
32289	Frank Pietrantonio	703-456-8567
33885	William Galliani	650-843-5622
34262	C Talbot	703-456-8072
36977	Kevin Zimmer	858-945-8634
41087	Christopher Hutter	703-456-8506
42887	Erik Milch	202-416-5845
43210	Michael Tuscan	202-842-7802
43255	Bonnie Mcleod	202-842-7800
43360	Nan Wu	415-693-2002
44051	Thomas Croft	248-864-5904
50501	Nancy Vashaw	703-456-8000
50834	Cliff Liu	650-843-5852
51793	Mark Hayman	617-951-8440
53087	Tamara Kale	650-779-2245
54092	Jason Fan	407-841- 2343
55854	Scott Weston	617-937-2327
56414	John Mills	571-299-2062
57403	Kyle Pendergrass	858-231-2473
57835	Phillip Morton	703-456-8000
59129	Jeffery Wyzykowski	202-842-7800
59307	David Hopkins	720-566-4063
59855	Steven Tietsworth	858-244-5939
61469	Christopher James	703-456-8539
61689	Margaret Fischofer	703-456-8000
62305	Jennifer Volk	703-456-8575
63322	Eamonn Gardner	858-550-6086
64349	Andrew Keith	202-842-7800
65210	Christina Macdougall	415-442-1277
66418	Jonathan Cousin	202-842-7800
70211	Jason Valentine	202-728-7157
L0625	Yi Wang	202-728-7128

Proceeding Documents

132

JUDGMENT Granting Motion to Terminate and Request for Adverse Judgment after Institution of Trial 37 C.F.R. § 42.73(b) ADVRSJUDG

2025-10-27 FILING PARTY: BOARD

Download

3007

Email from Petitioner re non-opposition to Patent Owner’s Motion requesting Acceptance Exhibit

2025-10-27 FILING PARTY: BOARD

Download

ORDER Granting Patent Owner’s Motion Requesting Acceptance of Submission of Patent Owner’s Request for Adverse Judgment and Motion to Terminate Filed under Board’s Alternative Means 37 C.F.R. § 42.6(b)(2)(i) ORDER

2025-10-27 FILING PARTY: BOARD

Download

3006

Email from Patent Owner re Request for Authorization to File Motion to Terminate etc. Exhibit

2025-10-27 FILING PARTY: BOARD

Download

2026

Disclaimer for US Patent No. 8,771,729 Exhibit

2025-10-24 FILING PARTY: PATENT OWNER

Download

DR. FALK PHARMA GMBH vs. Ellodi Pharmaceuticals LP

Proceeding Overview

Parties & Counsel

Petitioner

DR. FALK PHARMA GMBH

Represented By

Patent Owner / Respondent

Ellodi Pharmaceuticals LP

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

JUDGMENT Granting Motion to Terminate and Request for Adverse Judgment after Institution of Trial 37 C.F.R. § 42.73(b) ADVRSJUDG

Email from Petitioner re non-opposition to Patent Owner’s Motion requesting Acceptance Exhibit

ORDER Granting Patent Owner’s Motion Requesting Acceptance of Submission of Patent Owner’s Request for Adverse Judgment and Motion to Terminate Filed under Board’s Alternative Means 37 C.F.R. § 42.6(b)(2)(i) ORDER

Email from Patent Owner re Request for Authorization to File Motion to Terminate etc. Exhibit

Disclaimer for US Patent No. 8,771,729 Exhibit

Patent Owner's Motion Requesting Acceptance of Submission of Patent Owner’s Request for Adverse Judgment and Motion to Terminate Filed Under Board’s Alternative Means MOTION

Patent Owner's Updated Exhibit List NOTICE

Patent Owner's Request for Adverse Judgment MOTION

Ex 3005 Exhibit

Petitioner's Updated Exhibit List NOTICE

Petitioner Dr. Falk Pharma’s Demonstrative Exhibits For Oral Hearing Exhibit

Order: Setting Oral Argument 37 C.F.R. sec. 42.70 ORDER

Petitioner's Supplemental Mandatory Notice: Related Matters Section NOTICE

General Order: Related Matters Updates ORDER

Petitioner's Request for Oral Argument OTHER

Patent Owner's Request for Oral Hearing MOTION

Petitioner's Opposition to Patent Owner's Motion to Strike OPPOSITION

Patent Owner's Corrected Surreply RESPONSE

Ex. 3004 Exhibit

U.S. Patent No. 8,324,192 Exhibit

Cordova-Fraga T, Sosa M, Wiechers C, et al., Effects of anatomical position on esophageal transit time: a biomagnetic diagnostic technique. World J Gastroenterol 14:5707–11 (2008) Exhibit

Ghosh, T.K. et al, Drug Delivery to the Oral Cavity Molecules to Market, Ch. 14 Quick dissolving oral dosage forms: Scientific and regulatory considerations from a clinical pharmacology and Biopharmaceutics Perspective (2005) Exhibit

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, Patent and Exclusivity for: N213976, Product 001 Budesonide (Eohilia) Suspension 2mg/10ml Exhibit

Hahm, HA, Augsberger, LL, Ch 9 Orally Disintegrating Tablets and Related Tablet Formulations Exhibit

Transcript of the August 25, 2025 deposition of Alan Parr, Pharm.D. Exhibit

International Publication No. WO 2009/006516 A1 Exhibit

Guidance for Industry, Dissolution Testing of Immediate Release Solid Oral Dosage Forms, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (August 1997) Exhibit

Memorandum from Director Coke Morgan Stewart to Members of the Patent Trial and Appeal Board re Enforcement and Non-Waiver of 37 C.F.R. § 42.104(B)(4) and Permissible Uses of General Knowledge in Inter Partes Reviews, dated July 31, 2025 Exhibit

Patent Owner's Surreply RESPONSE

Patent Owner's Motion to Strike Exhibits 1075-1082, Portions of Petitioner’s Reply Brief and Dr. Parr’s Reply Declaration MOTION

Petitioner's Updated Exhibit List NOTICE

August 14, 2025 Oral Hearing Transcript Regarding Patent Owner Request for Authorization to File a Motion to Strike in IPR2024- 01197 Exhibit

Ex. 3003 Exhibit

Joint Stipulation to Modify Due Date 3 OTHER

Patent Owner's Notice of Deposition of Alan F. Parr, Pharm.D., Ph.D. NOTICE

Patent Owner's Objections to Petitioner's Evidence Submitted with Petitioner Reply OTHER

International Publication No. WO2009078872 to Martin et al. Exhibit

Schoepfer et al., “Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis,” Clinical Gastroenterology and Hepatology, 17:1477- 1488 (2019) Exhibit

ZOFRAN® (ondansetron) FDA-approved package insert Exhibit

PEPCID® (famotidine) FDA-approved package insert Exhibit

U.S. Patent Publication No. 20030124184 to Mezaache et al. Exhibit

U.S. Patent No. 7,384,921 to Tang et al. Exhibit

Petitioner's Reply Brief OTHER

Khan et al., “Taste masking of ondansetron hydrochloride by polymer carrier system and formulation of rapid-disintegrating tablets,” AAPS PharmSciTech 8:E1-E7 (2007) Exhibit

Than, “Individualized Drugs for Individual Needs,” Review of Optometry, 146:38-43 (2009) Exhibit

U.S. Patent No. 6,139,865 to Friend et al. Exhibit

CLARITIN® (loratadine) FDA-approved package insert Exhibit

2021-04-19 Assignment of U.S. Patent No. 8,771,729 from Adare Pharmaceuticals US, L.P. to Ellodi Pharmaceuticals, L.P. recorded at Reel 055966, Frame 0658 Exhibit

U.S. Patent Publication No. 20090022799 to Barman Exhibit

2015-09-18 Assignment of U.S. Patent Application No. 10/827,106 (which published as Venkatesh, EX1020) to Adare Pharmaceuticals, Inc. recorded at Reel 036554, Frame 0829 Exhibit

2025-07-02 Deposition transcript of Dr. Martyn Davies Exhibit

U.S. Publication No. US20110189299 to Okubo and Davies et al. Exhibit

2015-09-18 Assignment of U.S. Patent No. 6,139,865 to Adare Pharmaceuticals, Inc. recorded at Reel 036640, Frame 0591 Exhibit

International Publication No. WO2003074029 to McEntee et al. Exhibit

U.S. Patent Publication No. 20080132535 to Singh et al. Exhibit

CLARINEX® (desloratadine) FDA-approved package insert Exhibit

Declaration of Alan F. Parr, Pharm.D., Ph.D. supporting Petitioner Reply for U.S. 8,771,729 Exhibit

U.S. Patent Publication No. 20050019393 to Augsburger et al. Exhibit

Narmada et al., “Formulation, evaluation and optimization of fast dissolving tablets containing amlodipine besylate by sublimation method,” ARS Pharmaceutica, 50:129-144 (2009) Exhibit

Iorgulescu, “Saliva between normal and pathological. Important factors in determining systemic and oral health,” Journal of Medicine and Life 2:3003-307 (2009) Exhibit

Petitioner's Updated Exhibit List NOTICE

Petitioner's Notice of Deposition of Dr. Martyn Christopher Davies NOTICE

U.S. Patent Application Publication No. 2005/0009848 A1 Exhibit

“Lozenge” Definition, Dennis B. Worthen (ed.), Dictionary of Pharmacy (2004) Exhibit

Clinical Trials Study, “Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)(FLUTE),” last updated Apr. 26, 2023 Exhibit